Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15286 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Chen Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chung Shan Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Hydroxychloroquine, Osteoporosis, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Aim
Patients with rheumatoid arthritis (RA) are at a higher risk of osteoporotic fractures. Studies have shown that patients with Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) experienced an increase in bone mineral density (BMD) after receiving hydroxychloroquine (HCQ) treatment, indicating a potential protective effect against osteoporosis. Therefore, this study is to examine the relationship between HCQ usage and the risk of osteoporosis in patients diagnosed with RA.
Methods
The retrospective cohort study used data from Taiwan's National Health Insurance Research Database (NHIRD) covering the period from January 2010 to December 2018, which included 14 050 newly diagnosed RA patients, subsequently divided into two groups: HCQ users and non‐users. Propensity score matching (PSM) based on sex, age, urbanization, insured unit type, insured area, and comorbidities was conducted to match the groups. The primary outcome assessed was the evaluation of the risk of osteoporosis by employing a multivariable Cox proportional hazard regression model to calculate the adjusted hazard ratio (aHR).
Results
After PSM, a total of 6408 RA patients were included in the analysis (3204 HCQ users and 3204 non‐users). There was no significantly higher risk of osteoporosis in HCQ users compared with non‐users, aHR = 0.99 (95% CI: 0.82–1.196). Additionally, different durations of HCQ usage demonstrated a neutral effect on the risk of osteoporosis [HCQ 180 days, aHR = 1.019 (95% CI: 0.832–1.249)].
Conclusions
The study indicates that there is no significant association between the use of HCQ and the risk of osteoporosis in patients with RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Recreational Sport & Health Promotion, National Pingtung University of Science and Technology, Pingtung, Taiwan.
ORCID-Profile: Chen Dong, Brian Shiian Chen
Zitieren
APA
Dong, C., Chen, B. S., Wu, C. H., Chiu, Y. M., Liao, P. L., & Perng, W. T. (2024). Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15286
Vancouver
Dong C, Chen BS, Wu CH, Chiu YM, Liao PL, Perng WT. Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15286
BibTeX
@article{Dong2024,
author = {Dong, Chen and Chen, Brian Shiian and Wu, Chun Hsien and Chiu, Yi-Ming and Liao, Pei-Lun and Perng, Wuu-Tsun},
title = {Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15286}
}
EUVIMED